ARCH Venture Fund VII, L.P.'s Net Worth

$167 Million

Who is ARCH Venture Fund VII, L.P.?

ARCH Venture Fund VII, L.P. has an estimated net worth of $167 Million. This is based on reported shares across multiple companies, which include PHASERX, INC., AGIOS PHARMACEUTICALS INC, Neumora Therapeutics, Inc., Receptos, Inc., 908 Devices Inc., Pulmatrix, Inc., bluebird bio, Inc., Twist Bioscience Corp, Sage Therapeutics, Inc., Unity Biotechnology, Inc., Syros Pharmaceuticals, Inc., and Juno Therapeutics, Inc..

SEC CIK

ARCH Venture Fund VII, L.P.'s CIK is 0001402439

Past Insider Trading and Trends

2013 was ARCH Venture Fund VII, L.P.'s most active year for acquiring shares with 6 total transactions. ARCH Venture Fund VII, L.P.'s most active month to acquire stocks was the month of June. 2014 was ARCH Venture Fund VII, L.P.'s most active year for disposing of shares, totalling 13 transactions. ARCH Venture Fund VII, L.P.'s most active month to dispose stocks was the month of June. 2020 saw ARCH Venture Fund VII, L.P. paying a total of $6,000,000.00 for 5,725,045 shares, this is the most they've acquired in one year. In 2014 ARCH Venture Fund VII, L.P. cashed out on 24,272,413 shares for a total of $1,345,906.01, their largest year based on trade value.